NCT00528645

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase II Study of the c-SRC Inhibitor AZD0530 After Four Cycles of Cytoreductive Chemotherapy for Patients With Extensive Stage Small Cell Lung Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II study is studying how well giving AZD0530 works in treating patients with extensive-stage small cell lung cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine the 12-week progression-free survival rate of patients with extensive stage small cell lung cancer treated with AZD0530. SECONDARY OBJECTIVES: I. To determine the response rate in patients treated with this drug. II. To determine the overall survival and time-to-progression in patients treated with this drug. III. To determine the adverse events of AZD0530 in these patients IV. To determine the effect of AZD0530 treatment on levels of circulating tumor cells in these patients. V. To determine potential predictive markers of response in circulating tumor cells after treatment with this drug. VI. To evaluate the rate of tumor marker (i.e., circulating tumor cells) stabilization in patients treated with this drug. TERTIARY OBJECTIVES: I. To determine the effect of AZD0530 treatment on levels of circulating tumor cells. II. To determine potential predictive markers of response in circulating tumor cells after treatment with this drug. III. To evaluate the rate of tumor marker (i.e., circulating tumor cells) stabilization in patients treated with this drug. OUTLINE: Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies. After completion of study therapy, patients are followed periodically for up to 2 years.

Conditions

• Extensive Stage Small Cell Lung Cancer
• Lung Metastases
• Malignant Pleural Effusion
• Recurrent Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	saracatinib	Given orally

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-11-01
• Completion: 2013-05-01
• First posted: 2007-09-12
• Last updated: 2017-12-07
• Results posted: 2014-02-11

Locations

1 site across 1 country: United States